このエントリーをはてなブックマークに追加
ID 50645
フルテキストURL
著者
Shien, Kazuhiko Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Toyooka, Shinichi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Ichimura, Kouichi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol
Soh, Junichi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Furukawa, Masashi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Maki, Yuho Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Muraoka, Takayuki Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Tanaka, Norimitsu Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Ueno, Tsuyoshi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Asano, Hiroaki Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Tsukuda, Kazunori Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Yamane, Masaomi Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Oto, Takahiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kiura, Katsuyuki Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Resp Med
Miyoshi, Shinichiro Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
抄録
The expression of several cancer stem cell (CSC)-related markers has been confirmed in non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC-related markers in patients with NSCLC undergoing induction chemoradiotherapy (CRT). Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. The expressions of CSC related markers (CD133, ALDH1, ABCG2, and Bmi-1) were examined using immunohistochemical staining in surgically resected specimens. Among the 50 patients, 20 patients had no residual tumor cells in the resected specimen when examined pathologically; CSC-related marker expressions and their correlation to survival were evaluated in the other 30 patients. After a median follow-up period of 72 months, the 5-year overall survival rate of the patients with CD133-positive or ALDH1-positive specimens was significantly worse than that of the patients with both CD133-negative and ALDH1-negative expressions (449% vs. 90.0%, respectively; P=0.042). In a multivariate analysis. CD133 and ALDH1 negativity (P=0.047) and cN2-3 single station metastasis (P=0.03) were significant independent prognostic factors for prolonged survival. The expressions of CSC-related markers after CRT were significantly correlated with a poor prognosis in patients with NSCLC. The development of therapeutic strategies including adjuvant therapy that take CSC-related marker positivity into consideration is likely to be a key factor in further improvements of the prognosis of patients undergoing trimodality therapy.
キーワード
NSCLC
Cancer stem cell
CD133
ALDH1
Chemoradiotherapy
Induction therapy
発行日
2012-07
出版物タイトル
Lung Cancer
77巻
1号
出版者
Elsevier Ireland Ltd.
開始ページ
162
終了ページ
167
ISSN
0169-5002
NCID
AA10785743
資料タイプ
学術雑誌論文
オフィシャル URL
http://dx.doi.org/10.1016/j.lungcan.2012.02.006
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/50697
言語
English
著作権者
(C) 2012 Elsevier Ireland Ltd. All rights reserved.
論文のバージョン
author
査読
有り
DOI
Web of Sience KeyUT